#4 - Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics (NASDAQ: CARA) - One of the primary missions of many medical marijuana companies is to create a viable alternative to opioids as a source of pain management. Cara is one of the leaders in this mission. Although they may look like a pharmaceutical company, the company is standing out on the leading edge of mining the pain-fighting properties of cannabis. Specifically, Cara has a drug in preclinical development, CR701, which uses the unique properties of cannabis to treat neuropathic pain. Buying into Cara is not considered a pure cannabis play, but as this market becomes more mature, there will be consolidation among the major cannabis growers and suppliers, and companies like Cara will present opportunities for investors to profit from the untapped opportunities that cannabis is unlocking. One concern is that CR701 could be several years away from becoming a viable contributor to Cara’s top and bottom line. However, someone has to be first. And if the trials go well, Cara will be a name to watch in the increasingly disruptive world of companies looking to capitalize on cannabis.
About Cara Therapeutics
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Read More - Current Price
- $0.42
- Consensus Rating
- Hold
- Ratings Breakdown
- 0 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $2.32 (449.0% Upside)
